Cargando…

Epigallocatechin-3-Gallate Prevents Acute Gout by Suppressing NLRP3 Inflammasome Activation and Mitochondrial DNA Synthesis

Gout is a chronic inflammatory disease evoked by the deposition of monosodium urate (MSU) crystals in joint tissues. The nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) family pyrin domain containing 3 (NLRP3) inflammasome is responsible for the gout inflammatory symptoms induced...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Hye Eun, Yang, Gabsik, Park, Youn Bum, Kang, Han Chang, Cho, Yong-Yeon, Lee, Hye Suk, Lee, Joo Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600669/ https://www.ncbi.nlm.nih.gov/pubmed/31174271 http://dx.doi.org/10.3390/molecules24112138

Ejemplares similares

Loganin Alleviates Gout Inflammation by Suppressing NLRP3 Inflammasome Activation and Mitochondrial Damage
por: Choi, Nuri, et al.
Publicado: (2021)

Inhibition of NLRP3 inflammasome in tumor microenvironment leads to suppression of metastatic potential of cancer cells
por: Lee, Hye Eun, et al.
Publicado: (2019)

Targeting ASC in NLRP3 inflammasome by caffeic acid phenethyl ester: a novel strategy to treat acute gout
por: Lee, Hye Eun, et al.
Publicado: (2016)

Sweroside Prevents Non-Alcoholic Steatohepatitis by Suppressing Activation of the NLRP3 Inflammasome
por: Yang, Gabsik, et al.
Publicado: (2020)

Loganin Prevents Hepatic Steatosis by Blocking NLRP3 Inflammasome Activation
por: Jang, Joo Hyeon, et al.
Publicado: (2023)

Natural Products as a Novel Therapeutic Strategy for NLRP3 Inflammasome-Mediated Gout
por: Lee, Jun Ho, et al.
Publicado: (2022)

Improvement Effect of Soyeom Pharmacopuncture on Gout via NLRP3 Inflammasome Regulation
por: Kim, Sung Wook, et al.
Publicado: (2022)

A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet
por: Yang, Gabsik, et al.
Publicado: (2016)

Erratum: A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet
por: Yang, Gabsik, et al.
Publicado: (2016)

Repurposing Auranofin, an Anti-Rheumatic Gold Compound, to Treat Acne Vulgaris by Targeting the NLRP3 Inflammasome
por: Yang, Gabsik, et al.
Publicado: (2020)

The role of the NLRP3 inflammasome in gout
por: Kingsbury, Sarah R, et al.
Publicado: (2011)

Therapeutic regulation of the NLRP3 inflammasome in chronic inflammatory diseases
por: Seok, Jin Kyung, et al.
Publicado: (2021)

Regulation of the NLRP3 Inflammasome by Post-Translational Modifications and Small Molecules
por: Seok, Jin Kyung, et al.
Publicado: (2021)

Epigallocatechin-3-gallate suppresses hemin-aggravated colon carcinogenesis through Nrf2-inhibited mitochondrial reactive oxygen species accumulation
por: Seok, Ju Hyung, et al.
Publicado: (2022)

Sinapic Acid Controls Inflammation by Suppressing NLRP3 Inflammasome Activation
por: Lee, Eun Hye, et al.
Publicado: (2021)

Inflammasomes and their roles in arthritic disease pathogenesis
por: Yang, Gabsik, et al.
Publicado: (2022)

Selective Inhibitory Effect of Epigallocatechin-3-gallate on Migration of Vascular Smooth Muscle Cells
por: Han, Dong-Wook, et al.
Publicado: (2010)

Effects of Epigallocatechin-3-Gallate on Autophagic Lipolysis in Adipocytes
por: Kim, Sang-Nam, et al.
Publicado: (2017)

MARCH5‐dependent NLRP3 ubiquitination is required for mitochondrial NLRP3‐NEK7 complex formation and NLRP3 inflammasome activation
por: Park, Yeon‐Ji, et al.
Publicado: (2023)

Grape seed-derived procyanidins alleviate gout pain via NLRP3 inflammasome suppression
por: Liu, Hai-Jiao, et al.
Publicado: (2017)

Anticancer activities of epigallocatechin-3-gallate against cholangiocarcinoma cells
por: Kwak, Tae Won, et al.
Publicado: (2016)

Skin Protective Effect of Epigallocatechin Gallate
por: Kim, Eunji, et al.
Publicado: (2018)

Epigallocatechin-3-gallate rescues LPS-impaired adult hippocampal neurogenesis through suppressing the TLR4-NF-κB signaling pathway in mice
por: Seong, Kyung-Joo, et al.
Publicado: (2016)

The Mechanism of the NLRP3 Inflammasome Activation and Pathogenic Implication in the Pathogenesis of Gout
por: Kim, Seong-Kyu
Publicado: (2022)

Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant
por: Cheong, Yucheol, et al.
Publicado: (2021)

Epigallocatechin-3-gallate and Epigallocatechin-3-O-(3-O-methyl)-gallate Enhance the Bonding Stability of an Etch-and-Rinse Adhesive to Dentin
por: Yu, Hao-Han, et al.
Publicado: (2017)

Lower Temperatures Exacerbate NLRP3 Inflammasome Activation by Promoting Monosodium Urate Crystallization, Causing Gout
por: Ahn, Huijeong, et al.
Publicado: (2021)

Effects of epigallocatechin-3-gallate combined with ascorbic acid and glycerol on the stability and uric acid-lowering activity of epigallocatechin-3-gallate
por: Xie, Qianjin, et al.
Publicado: (2021)

Epigallocatechin-3-gallate inhibits osteoclastic differentiation by modulating mitophagy and mitochondrial functions
por: Sarkar, Jaganmay, et al.
Publicado: (2022)

A Novel Treatment Strategy by Natural Products in NLRP3 Inflammasome-Mediated Neuroinflammation in Alzheimer’s and Parkinson’s Disease
por: Lee, Jun Ho, et al.
Publicado: (2021)

Small heterodimer partner interacts with NLRP3 and negatively regulates activation of the NLRP3 inflammasome
por: Yang, Chul-Su, et al.
Publicado: (2015)

Antioxidant and Cytoprotective Effects of (−)-Epigallocatechin-3-(3″-O-methyl) Gallate
por: Kim, Eunji, et al.
Publicado: (2019)

Epigallocatechin-3-Gallate Suppresses Vasculogenic Mimicry through Inhibiting the Twist/VE-Cadherin/AKT Pathway in Human Prostate Cancer PC-3 Cells
por: Yeo, Changhwan, et al.
Publicado: (2020)

Epigallocatechin gallate attenuates L-DOPA-induced apoptosis in rat PC12 cells
por: Lee, Myung-Yul, et al.
Publicado: (2013)

Effects of epigallocatechin-3-gallate on thermogenesis and mitochondrial biogenesis in brown adipose tissues of diet-induced obese mice
por: Lee, Mak-Soon, et al.
Publicado: (2017)

Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG)
por: Singh, Neha Atulkumar, et al.
Publicado: (2016)

Inhibitory Effects of (−)-Epigallocatechin-3-gallate on Esophageal Cancer
por: Wang, Liu-Xiang, et al.
Publicado: (2019)

Melatonin and (−)-Epigallocatechin-3-Gallate: Partners in Fighting Cancer
por: Zhang, Lingyun, et al.
Publicado: (2019)

Anticancer effects and molecular mechanisms of epigallocatechin-3-gallate
por: Min, Kyoung-jin, et al.
Publicado: (2014)

Antiallodynic effect of intrathecal epigallocatechin-3-gallate due to suppression of reactive oxygen species
por: An, Sang Soon, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_40qj9jvp6rigmikpltvo91k477